Our Promise to You

Guaranteed product quality, expert customer support

Our Promise to You

MHH-CALL-3

  • Specification
  • Recommended Products
Cat.No.
CSC-C0398
Description
Established from the bone marrow of an 11-year-old girl with pre B cell acute lymphoblastic leukemia (ALL) in 1993 (at diagnosis)
Species
Human
Source
B cell precursor leukemia
Recommended Medium
Culture Properties
suspension
Morphology
single, relatively small round cells growing in suspension
Karyotype
Human pseudodiploid karyotype - 46(45-46)<2n>XX, del(6)(q15), der(9)t(9;9)(p21;q11), der(19)t(1;19)(q23;p13) - carries t(1;19) primary and 6q- secondary rearrangements associated with pre B-ALL - resembles published karyotype
Quality Control
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization, PCR assays
Immunology: CD3 -, CD10 +, CD13 -, CD19 +, CD20 +, CD34 -, CD38 +, cyCD79a +, CD80 -, CD138 +, HLA-DR +
Viruses: ELISA: reverse transcriptase negative; PCR: EBV -, HBV -,
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 4 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

For research use only. Not for any other purpose.

  • Background
  • Scientific Data
  • Q & A
  • Customer Review
  • Product Information Sheet

The MHH-CALL-3 cell line is a well-known cell line derived from the bone marrow of an 11-year-old girl diagnosed with pre-B cell acute lymphoblastic leukemia (ALL) in 1993. The MHH-CALL-3 cell line represents a specific subtype of pre-B cell ALL and has provided important insights into the disease.

The MHH-CALL-3 cell line has been extensively characterized, including analysis of its immunophenotype, genetic abnormalities, gene expression profiles, and responses to various treatments. These studies have provided valuable information about the molecular pathways involved in pre-B cell ALL and have contributed to the identification of potential therapeutic targets.

Researchers have used the MHH-CALL-3 cell line to study the efficacy of different chemotherapeutic agents, targeted therapies, and immunotherapies in pre-B cell ALL. This cell line has also been utilized to investigate the signaling pathways, genetic mutations, and gene expression patterns associated with the development and progression of the disease.

Bortezomib Induces Apoptosis in Prednisone-Resistant Childhood ALL Cells

The ubiquitin-proteasome degradation pathway (UPDP) is possibly altered and may be involved in multi-agent chemotherapy resistance in childhood ALL patients. The proteasome inhibitor bortezomib blocks proteasomal degradation and hence the UPDP. To investigate whether treatment of ALL with the proteasome inhibitor bortezomib acts synergistically with glucocorticoid treatment, human B-cell precursor leukemic cell lines MHH cALL 2 (PPR) and MHH cALL 3 (PGR) were treated with prednisone (6.2 μM) and various concentrations of bortezomib (1.5-12 nM) for up to 96 hours.

Both cell lines showed a dose-dependent increase in apoptosis after bortezomib single treatment (Fig. 1). Single therapy with 12 nM bortezomib-induced in PGR a 42-fold and in PPR cells a 29-fold higher caspase activity compared to treatment with prednisone alone. However, only the PGR cells showed an additive effect on apoptosis induction after combined treatment with prednisone and bortezomib. In the PPR cell line, the amount of PI-positive, lethal cells increased within 48 hours to 20-fold after combined treatment, using 7 nM bortezomib, compared to single prednisone, and 3-fold compared to single bortezomib treatment. In contrast, apoptosis was reduced compared to bortezomib single treatment.

Fig. 1 Increase of PI-positive cells in human B-cell precursor ALL cell lines (MHH cALL 2 and MHH cALL 3). (Junk S, et al., 2009)Fig. 1 Increase of PI-positive cells in human B-cell precursor ALL cell lines (MHH cALL 2 and MHH cALL 3). (Junk S, et al., 2009)

Expression of Mer in ALL Cell Lines Correlates with a Quiescent Phenotype in CNS Cocultures

Patients with t(1;19)-positive ALL are prone to central nervous system (CNS) relapses, and expression of the TAM (Tyro3, Axl, and Mer) receptor Mer is upregulated in these leukemias. High Mer expression was detected in MHH-CALL3 and 697 cells with the t(1;19) translocation and REH and UoCB6 cells with the t(12;21) translocation. Low or absent Mer expression was found in SUP-B15 cells carrying the t(9;22) translocation, RS4;11 cells with t(4;11), and in the promyelocytic AML cell line HL-60 (Fig. 2A).

Hypothesizing a role for CNS glia in supporting the survival of Mer-expressing ALL cells, a coculture model with U343 cells was established derived from a low-grade mixed astrocytoma/oligodendroglioma. Coculture of ALL cell lines with U343 for 48 hours resulted in a reduction of viable cells in all cell lines analyzed (Fig. 2B). The observed effect was more pronounced in Merhigh cells and less appreciable in Merlow cells (Fig. 2B). U343 coculture induced a quiescent phenotype in ALL cells characterized by an arrest in G0/G1 and a drop in S-phase (Fig. 2C-H).

Fig. 2 U343 coculture induces quiescence in Mer-expressing ALL cell lines (MHH-CALL3, 697, REH, UoCB6, SUP-B15, and RS4;11). (Krause S, et al., 2015)Fig. 2 U343 coculture induces quiescence in Mer-expressing ALL cell lines (MHH-CALL3, 697, REH, UoCB6, SUP-B15, and RS4;11). (Krause S, et al., 2015)

Q:
What is the best IHC marker for multiple myeloma?
A:

CD56 has a good positive predictive value for the diagnosis of myeloma and correlates well with bone lesions, and may be correlated with the pathogenesis of lytic lesions.

Q:
What is the disease background of the MHH-CALL-3 cell line?
A:

MHH-CALL-3 cells were established from the bone marrow of an 11-year-old girl diagnosed with pre B cell acute lymphoblastic leukemia (ALL) at the time of diagnosis in 1993, serving as a relevant model to study this specific subtype of leukemia.

Q:
How can the MHH-CALL-3 cells contribute to our understanding of pre B cell ALL progression?
A:

By studying MHH-CALL-3 cells, researchers can gain insights into the disease progression, genetic aberrations, and cellular responses that underpin pre B cell ALL, aiding in the development of targeted therapeutic strategies.

Q:
What are the primary research applications of the MHH-CALL-3 cell line?
A:

The MHH-CALL-3 cells are utilized in preclinical studies, drug screening assays, and molecular investigations to further our understanding of pre B cell ALL progression and test potential therapeutic interventions.

Ask a Question

Average Rating: 4.7    |    3 Scientist has reviewed this product

Helpful

Cells are the foundation of research, and Creative Bioarray's products and services have been a great help to me.

19 Oct 2022


Ease of use

After sales services

Value for money


Exceptional research tools

The MHH-CALL-3 cell products from Creative Bioarray have been instrumental in my research on pre B cell acute lymphoblastic leukemia (ALL).

10 Jan 2024


Ease of use

After sales services

Value for money


Valuable tools

These cells accurately model the disease phenotype and have facilitated in-depth molecular and genetic studies, providing valuable insights into disease progression. I highly recommend these cell products for researchers studying pre B cell ALL.

17 Oct 2023


Ease of use

After sales services

Value for money


Write your own review

Customer Support & Price Inquiry

Verification Code